The SOLIDARITY trial includes hospitalized patients with COVID-19 from more than 90 countries around the world to compare treatment options with standard care and assess their relative effectiveness against SARS-CoV-2. By enrolling patients from multiple countries, the SOLIDARITY trial aims at rapidly discovering if any of the drugs mitigate disease progression or improve survival. According to the WHO director-general, the study will dramatically cut the time needed to generate robust evidence on how the drugs work. Thus, the two most promising treatment options selected were Remdesivir or Lopinavir/Ritonavir with IFN-β. Other drugs can be added based on emerging evidence (13).